CellCentric is a clinical stage biotechnology company focused on the development of the novel drug CCS1477 for prostate (CRPC) and other cancers.
The company is financed by long-term international venture capital investors led by Morningside Venture Investments. It has an experienced management team which has worked across major pharmaceutical as well as biotechnology companies.
CellCentric originally span out of the University of Cambridge, drawing on the work of one of the pioneers of epigenetics, Prof Azim Surani FRS CBE. Over time the company has investigated a wide range of epigenetic-related pathways to address disease, notably cancer. Over 50 potential drug targets have been explored. An early arginine methyltransferase programme was licenced to Takeda Pharmaceuticals.
From this breadth in epigenetic-related research, CellCentric has prioritised the development of first-in-class small molecule p300/CBP inhibitors for the treatment of late stage prostate and other cancers.